Seventure Partners
Seventure Partners, established in 1997, is a leading European venture capital firm headquartered in Paris, with additional offices in Munich, Geneva, London, and Basel. The company focuses on investing in innovative Tech/Digital and Life Sciences companies, with a global reach spanning North America, Europe, Asia-Pacific, Middle East, and Africa. Seventure Partners manages over €1 billion and employs around 20 professionals, including 15 investors. They actively support entrepreneurs in B2B SaaS, Fintech, Retailtech, Cybersecurity, Biotech, Healthcare, Nutrition, Sports & Wellbeing, and Blue Economy sectors, providing expertise, networks, and know-how to accelerate growth.
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
MaaT Pharma
Series B in 2020
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
MaaT Pharma
Series A in 2016
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
MaaT Pharma
Seed Round in 2015
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
MaaT Pharma
Seed Round in 2015
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.